

APPENDIX C – Sample COVID-19 Vaccination Medical Exemption Form

MEDICAL EXEMPTION TO DECLINE THE COVID-19 VACCINE

_____ has a medical exemption for the COVID-19 Vaccine in
Printed Name of Employee

relation to a condition indicated below.

The following conditions are the only absolute medical exemptions from the COVID-19 vaccine:

1. **Documented anaphylaxis** to a previous dose of COVID-19 vaccine or documented anaphylaxis to one of the vaccine components in authorized, available COVID-19 vaccines:

| Vaccine product | Potential allergen included in the vaccine or its container |
|----------------------------------|---|
| Pfizer-BioNTech COVID-19 vaccine | Polyethylene glycol (PEG) |
| Moderna COVID-19 vaccine | PEG Tromethamine (trometamol or Tris) |
| AstraZeneca COVID-19 vaccine | Polysorbate 80 |

Ref: see [NACI's Recommendations on the use of COVID-19 vaccines](#), Table 4 for complete details

These recommendations are in accordance with the guidance expressed by the National Advisory Committee on Immunizations (NACI) as of July 2, 2021 on non-medicinal ingredients of authorized, available COVID-19 vaccines that have been associated with allergic reactions in other products.

2. **Individuals with a history of myocarditis and/or pericarditis** should discuss the risks and benefits of receiving an mRNA vaccine or, alternately, the risks and benefits of receiving a viral vector vaccine (AstraZeneca) with their treating physician and/or primary care provider.
3. Very rare cases of **capillary leak syndrome (CLS)** have been reported following vaccination with viral vector vaccines (AstraZeneca COVID-19 Vaccine). Patients who have previously experienced episodes of CLS should not be vaccinated with AstraZeneca COVID-19 Vaccine or COVISHIELD but may receive an mRNA vaccine (Pfizer or Moderna).
4. **Individuals with a history of combined thrombosis and thrombocytopenia** should receive an mRNA vaccine. A combination of thrombosis and thrombocytopenia, in some cases accompanied by bleeding, has been observed very rarely following vaccination with the AstraZeneca COVID-19 Vaccine. Where an allergy precludes administration of an mRNA vaccine, individuals with a history of combined thrombosis and thrombocytopenia may discuss the risks and benefits of a viral vector vaccine (AstraZeneca) with their treating physician and/or primary care provider.

Physician Signature: _____ Date: _____

PLEASE NOTE: The information provided in this document does not contain legal advice and should not be relied on or treated as legal advice. Those for whom these recommendations are intended should seek their own legal advice to address their specific workplace circumstances.